🚀 VC round data is live in beta, check it out!
Kolon TissueGene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kolon TissueGene and similar public comparables like Shanghai Junshi, ABL Bio, PTC Therapeutics, Cogent Biosciences and more.
Kolon TissueGene Overview
About Kolon TissueGene
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.
Founded
1999
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$6B
Kolon TissueGene Financials
Kolon TissueGene reported last 12-month revenue of $4M and negative EBITDA of ($16M).
In the same LTM period, Kolon TissueGene generated $849K in gross profit, ($16M) in EBITDA losses, and had net loss of ($89M).
Revenue (LTM)
Kolon TissueGene P&L
In the most recent fiscal year, Kolon TissueGene reported revenue of $3M and EBITDA of ($14M).
Kolon TissueGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | $849K | XXX | $464K | XXX | XXX | XXX |
| Gross Margin | 21% | XXX | 13% | XXX | XXX | XXX |
| EBITDA | ($16M) | XXX | ($14M) | XXX | XXX | XXX |
| EBITDA Margin | (404%) | XXX | (406%) | XXX | XXX | XXX |
| EBIT Margin | (418%) | XXX | (425%) | XXX | XXX | XXX |
| Net Profit | ($89M) | XXX | ($130M) | XXX | XXX | XXX |
| Net Margin | (2208%) | XXX | (3720%) | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kolon TissueGene Stock Performance
Kolon TissueGene has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Kolon TissueGene's stock price is $72.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | -2.0% | XXX | XXX | XXX | $-1.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKolon TissueGene Valuation Multiples
Kolon TissueGene trades at 1486.0x EV/Revenue multiple, and (367.6x) EV/EBITDA.
EV / Revenue (LTM)
Kolon TissueGene Financial Valuation Multiples
As of April 18, 2026, Kolon TissueGene has market cap of $6B and EV of $6B.
Equity research analysts estimate Kolon TissueGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kolon TissueGene has a P/E ratio of (67.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 1486.0x | XXX | 1722.4x | XXX | XXX | XXX |
| EV/EBITDA | (367.6x) | XXX | (424.6x) | XXX | XXX | XXX |
| EV/EBIT | (355.1x) | XXX | (405.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 7077.6x | XXX | 12966.9x | XXX | XXX | XXX |
| P/E | (67.3x) | XXX | (46.3x) | XXX | XXX | XXX |
| EV/FCF | (74.4x) | XXX | (62.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kolon TissueGene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kolon TissueGene Margins & Growth Rates
Kolon TissueGene's revenue in the last 12 month grew by 43%.
Kolon TissueGene's rule of 40 is (345%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kolon TissueGene's rule of X is (264%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kolon TissueGene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | 55% | XXX | XXX | XXX |
| EBITDA Margin | (404%) | XXX | (406%) | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | 52% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (345%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (264%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 132% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 166% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 446% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kolon TissueGene Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kolon TissueGene | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Junshi | XXX | XXX | XXX | XXX | XXX | XXX |
| ABL Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| PTC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogent Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Caris Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kolon TissueGene M&A Activity
Kolon TissueGene acquired XXX companies to date.
Last acquisition by Kolon TissueGene was on XXXXXXXX, XXXXX. Kolon TissueGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kolon TissueGene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKolon TissueGene Investment Activity
Kolon TissueGene invested in XXX companies to date.
Kolon TissueGene made its latest investment on XXXXXXXX, XXXXX. Kolon TissueGene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kolon TissueGene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kolon TissueGene
| When was Kolon TissueGene founded? | Kolon TissueGene was founded in 1999. |
| Where is Kolon TissueGene headquartered? | Kolon TissueGene is headquartered in United States. |
| Is Kolon TissueGene publicly listed? | Yes, Kolon TissueGene is a public company listed on Korea Exchange. |
| What is the stock symbol of Kolon TissueGene? | Kolon TissueGene trades under 950160 ticker. |
| When did Kolon TissueGene go public? | Kolon TissueGene went public in 2017. |
| Who are competitors of Kolon TissueGene? | Kolon TissueGene main competitors are Shanghai Junshi, ABL Bio, PTC Therapeutics, Cogent Biosciences. |
| What is the current market cap of Kolon TissueGene? | Kolon TissueGene's current market cap is $6B. |
| What is the current revenue of Kolon TissueGene? | Kolon TissueGene's last 12 months revenue is $4M. |
| What is the current revenue growth of Kolon TissueGene? | Kolon TissueGene revenue growth (NTM/LTM) is 43%. |
| What is the current EV/Revenue multiple of Kolon TissueGene? | Current revenue multiple of Kolon TissueGene is 1486.0x. |
| Is Kolon TissueGene profitable? | No, Kolon TissueGene is not profitable. |
| What is the current EBITDA of Kolon TissueGene? | Kolon TissueGene has negative EBITDA and is not profitable. |
| What is Kolon TissueGene's EBITDA margin? | Kolon TissueGene's last 12 months EBITDA margin is (404%). |
| What is the current EV/EBITDA multiple of Kolon TissueGene? | Current EBITDA multiple of Kolon TissueGene is (367.6x). |
| What is the current FCF of Kolon TissueGene? | Kolon TissueGene's last 12 months FCF is ($81M). |
| What is Kolon TissueGene's FCF margin? | Kolon TissueGene's last 12 months FCF margin is (1998%). |
| What is the current EV/FCF multiple of Kolon TissueGene? | Current FCF multiple of Kolon TissueGene is (74.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.